Stansai completed 180 million yuan in Series B round of financing, which was jointly invested by Softbank China and others

Recently, Stansai Biotech Co., Ltd. has completed a new round of financing with a financing amount of 180 million yuan. This round of financing is made up of Volcanic Stone Investment, Goldtech Investment, Softbank China, Dunhou Capital, and Zhicheng Capital and other jointly funding institutions. In 2016, Stansai won the A-round investment of Dinghui Venture Capital and Jianqiao Capital Investment. Founder Xiao Lei said that this round of financing will be used for the next round of clinical trials.

Stansai Biotech is a cell therapy technology developer, specializing in the research and development of stem cells and regenerative medicine, new technologies in molecular biology, new materials and new products. It also provides several services related to molecular cell biology, including gene cloning, viral packaging, cell culture and transfection services.

In business, CD19 CAR-T, which is developed by Stansai Biological to treat advanced acute lymphoblastic leukemia, has undergone 39 clinical trials in the hematology department of more than 10 top three hospitals across the country since 2014, with a complete remission rate of 84.6%. MRD turnover rate reached 80%, reaching the international advanced level. CAR-T has also been successful in the treatment of lymphoma. Clinical trials targeting solid tumors such as breast cancer and pancreatic cancer and have also been initiated in multiple hospitals.

Talking about the transaction, Zhang Suyang, founding partner of volcanic stone, stated: “In recent years, emerging medical technologies based on gene technology have developed rapidly. Among them, immune cell therapy is a promising direction, and CAR-T cell therapy is a door, which not only provided a reference for the regulatory standardization of cell therapy, but also attracted the attention of the academic community and capital. I believe that more cell therapy technologies will emerge in the future.”

Cai Dajian, founder and chairman of the company, said: "With the marketing approval of CAR-T products and the release of CFDA's cellular product-related policies, the CAR-T industry has truly ushered in a new era. After many years of painstaking research and development, we have developed breakthrough cell therapy products as well as complete production and quality control systems, which are already in the leading position in the domestic CAR-T industry.The new cell therapy drug ICT19G1 declared by Stansea has also been acquired CDE's admissibility."